What Is a PDUFA Date?
A PDUFA date is the FDA’s target action date for deciding on a drug application. PDUFA stands for Prescription Drug User Fee Act.
Simple definition
A PDUFA date is the date by which the FDA is expected to take action on a drug approval application. The FDA may approve the drug, issue a Complete Response Letter, extend the review, request more information, approve with restrictions or approve with post-marketing requirements.
Read more: What Is a Complete Response Letter?
PDUFA date vs approval date
A PDUFA date is not a guaranteed approval date. It is the FDA’s target action date. The FDA can act before the date, on the date or extend the review.
Why PDUFA dates move biotech stocks
PDUFA dates can cause major stock moves because they are binary or near-binary catalysts. The move depends on how much approval is priced in, how important the drug is, label language, safety warnings, commercial opportunity, financing needs and investor expectations.
NDA vs BLA
An NDA is a New Drug Application, usually for small-molecule drugs. A BLA is a Biologics License Application, used for biologics such as antibodies, cell therapies, vaccines and certain immunotherapies.
Read more: What Is a BLA?
Standard review vs priority review
Under current FDA performance goals (PDUFA VII), the target for a standard review is roughly 10 months and the target for a priority review is roughly 6 months, measured from the application’s filing date. Priority review is reserved for drugs that may offer significant improvements in the safety or effectiveness of treating, diagnosing or preventing serious conditions. These are performance goals rather than hard legal deadlines, and priority review shortens the timeline without lowering the evidence bar or guaranteeing approval.
What can happen before a PDUFA date?
Pre-PDUFA signals include FDA application acceptance, priority review, advisory committee scheduling, advisory committee vote, label discussions, inspection issues, manufacturing questions, safety concerns and information requests.
Investor checklist
Ask whether the pivotal trial was clearly positive, whether the endpoint was clinically meaningful, whether there were safety concerns, whether an AdCom is scheduled, whether inspections are needed, what label is expected and whether approval is priced in.
Frequently asked questions
What is a PDUFA date?
A PDUFA date is the FDA’s target action date for deciding on a drug application, named after the Prescription Drug User Fee Act. By this date the FDA is expected to act: it may approve the drug, issue a Complete Response Letter, extend the review, request more information, or approve with restrictions or post-marketing requirements. It is a target, not a guaranteed approval date.
Is a PDUFA date the same as an approval date?
No. A PDUFA date is the FDA’s target date to take action, not a promise to approve. The FDA can act before the date, on the date, or extend the review. If the drug is approved, the PDUFA date often becomes the approval date, but the outcome can also be a Complete Response Letter or a delay.
How long is a standard FDA review versus a priority review?
Under current FDA performance goals, a standard review targets roughly 10 months and a priority review targets roughly 6 months, measured from the application’s filing date. Priority review is reserved for drugs that may significantly improve the treatment, diagnosis or prevention of serious conditions. These are performance goals rather than legal deadlines, and priority review does not lower the evidence bar or guarantee approval.
What is the difference between an NDA and a BLA?
An NDA (New Drug Application) is usually used for small-molecule drugs, while a BLA (Biologics License Application) is used for biologics such as antibodies, cell and gene therapies, vaccines and certain immunotherapies. Both are submitted to the FDA for approval, and both receive a PDUFA target action date once the application is accepted for review.
Bottom line
A PDUFA date is a major biotech catalyst, but it is not a guarantee of approval. What outcome is already priced in, and what could still go wrong?